Celgene Corp (CELG.O)

CELG.O on Nasdaq

93.12USD
23 Sep 2014
Price Change (% chg)

$0.93 (+1.01%)
Prev Close
$92.19
Open
$91.80
Day's High
$93.60
Day's Low
$91.62
Volume
4,182,848
Avg. Vol
4,301,001
52-wk High
$96.44
52-wk Low
$66.85

CELG.O

Chart for CELG.O

About

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. It is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in... (more)

Overall

Beta: 1.11
Market Cap (Mil.): $73,706.84
Shares Outstanding (Mil.): 799.51
Dividend: --
Yield (%): --

Financials

  CELG.O Industry Sector
P/E (TTM): 53.16 33.02 33.86
EPS (TTM): 1.73 -- --
ROI: 12.30 18.15 17.39
ROE: 28.55 18.85 18.25
Search Stocks

Celgene's psoriasis drug gets approval for new indication

- Celgene Corp said U.S. health regulators have approved the expanded use of its drug Otezla for treating patients with moderate to severe plaque psoriasis.

4:22pm EDT

Celgene's psoriasis drug gets approval for new indication

Sept 23 - Celgene Corp said U.S. health regulators have approved the expanded use of its drug Otezla for treating patients with moderate to severe plaque psoriasis.

4:11pm EDT

UK cost agency backs Celgene bone marrow drug in change of tack

LONDON - Celgene's drug Revlimid should be an option on Britain's state health service for patients with serious bone marrow disorders and a specific chromosomal abnormality, the country's cost agency said on Wednesday.

19 Aug 2014

UK cost agency backs Celgene bone marrow drug in change of tack

LONDON, Aug 20 - Celgene's drug Revlimid should be an option on Britain's state health service for patients with serious bone marrow disorders and a specific chromosomal abnormality, the country's cost agency said on Wednesday.

19 Aug 2014

Celgene profit rises but revised outlook disappoints

- Celgene Corp reported a 25 percent rise in second-quarter profit, edging out Wall Street expectations, but a raised 2014 forecast failed to excite investors and its shares fell nearly 4 percent.

24 Jul 2014

UPDATE 2-Celgene profit rises but revised outlook disappoints

* Raises 2014 revenue, adjusted earnings-per-share forecast

24 Jul 2014

Celgene profit rises 25 pct up on higher cancer drug sales

July 24 - Celgene Corp reported a 25 percent increase in quarterly profit, helped by robust sales of its flagship cancer drug, Revlimid.

24 Jul 2014

Celgene drug can drive HIV out of hiding: study

LONDON - An anti-cancer drug made by the U.S. biotech firm Celgene can re-activate hidden HIV in patients so that it can be detected, bringing researchers closer to being able to treat it, Danish scientists said on Tuesday.

22 Jul 2014

Celgene drug can drive HIV out of hiding -study

* Scientists say finding is significant step in AIDS fight

22 Jul 2014

Celgene's spondylitis drug misses main goal in trial

- Celgene Corp said a drug being tested to treat a type of arthritis that affects the spine failed to meet the main goal in a late-stage trial, sending the company's shares down 3 percent premarket.

09 Jul 2014

Competitors

  Price Change
Takeda Pharmaceutical Co Ltd (4502.T) ¥4,928 +34.50
Eisai Co., Ltd (4523.T) ¥4,500 +57.00
Johnson & Johnson (JNJ.N) $107.46 -0.42
Pfizer Inc. (PFE.N) $30.05 -0.13
Novartis AG (NOVN.VX) CHF87.75 -0.50
Merck & Co., Inc. (MRK.N) $60.28 -0.30
Roche Holding Ltd. (ROG.VX) CHF282.20 -1.00
Abbott Laboratories (ABT.N) $42.50 -0.90
Sanofi SA (SASY.PA) €87.41 -1.46
AstraZeneca plc (AZN.L) 4,414.00p -163.50

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks